An Interview with Dr. Kristin Highland on Systemic Sclerosis
Dr. Highland is fellowship-trained in both pulmonary/critical care and
rheumatology. She is a member of the Respiratory Institute of the
Cleveland Clinic Foundation located in Ohio. Dr. Highland’s research interests have focused on interstitial lung
disease and pulmonary hypertension with an emphasis on scleroderma.
Exploring Sources of Emotional Distress among People Living with Scleroderma - A Case Study
The main finding of this case study was that sources of emotional distress for people with scleroderma are multifaceted in nature, begin prior to the diagnosis, and continue throughout their lives in an unpredictable manner.
Cytori Update on Its U.S. Phase III Scleroderma Trial
Cytori Therapeutics, Inc. announced that its U.S. FDA
approved Phase III STAR trial has enrolled and treated its 40th
patient (50% of target enrollment). In addition, a pre-specified
independent data monitoring committee review of safety data from the
initial 20 patients has been conducted and the committee has recommended
that the study continue as planned.
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
The Scleroderma Foundation is a qualified national nonprofit operating under 501(c)(3) status. The foundation’s federal tax identification number is 52-1375827. Our primary goal is to raise funds for our three-fold mission of support, education and research. The foundation has 20 active chapters and 160 support groups across the country.